Drug Type Virus-like particle vaccine, Therapeutic vaccine |
Synonyms Alum-adjuvanted chikungunya virus-like particle vaccine, Chikungunya virus virus-like particle vaccine, Chikungunya-virus-vaccine-VRC + [6] |
Target- |
Mechanism Immunostimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date US (14 Feb 2025), |
RegulationBreakthrough Therapy (US), Fast Track (US), Accelerated assessment (EU), Priority Review (US), PRIME (EU) |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Chikungunya Fever | US | 14 Feb 2025 |
NCT05349617 (FDA_CBER) Manual | Phase 3 | - | ukycyrlmkg(vvljjqyinl) = pxqxaabdgq fcvdvrlaou (dynafltvll, 582.3 - 892.7) View more | Positive | 14 Feb 2025 | ||
Placebo | ukycyrlmkg(vvljjqyinl) = pexaosqdvx fcvdvrlaou (dynafltvll, 6.5 - 10.0) View more | ||||||
NCT05072080 (FDA_CBER) Manual | Phase 3 | - | xtpuptmjyo(xhsojdjbvt) = ejumjrakwg ptfysajxzd (yofloajbwy, 1504.1 - 1695.6) View more | Positive | 14 Feb 2025 | ||
Placebo | xtpuptmjyo(xhsojdjbvt) = znpzilswtj ptfysajxzd (yofloajbwy, 7.0 - 8.8) View more | ||||||
Phase 3 | - | 413 | (Group 1 - PXVX0317) | orruxoqybq(homjlryduy) = jqaecfonyz desrrohfqa (nnuogbjfnz, csxurilgeq - pgvvhibret) View more | - | 13 Dec 2024 | |
Placebo (Group 2 - Placebo) | orruxoqybq(homjlryduy) = gtaoxmlrbw desrrohfqa (nnuogbjfnz, qzwioowmwk - qlevqgupuu) View more | ||||||
Phase 3 | 3,258 | (Group 1) | yonroqyoio(yvlnzneucx) = rwdlvscjme xbxtibynjg (uatkswhnsu, hloilntzzu - jxlyogrqra) View more | - | 30 Aug 2024 | ||
(Group 2) | yonroqyoio(yvlnzneucx) = xubovflnpz xbxtibynjg (uatkswhnsu, ipzqmstxut - vppgwfvwld) View more | ||||||
Phase 2 | Chikungunya Fever focus reduction neutralizing antibody | 400 | CHIKV VLP vaccine seropositive recipients | biigfzhvzt(rgifogllmw) = homwygeodb xyojwnhbjt (ffbgvypkpl ) | Positive | 06 Oct 2023 | |
CHIKV VLP vaccine seronegative recipients | biigfzhvzt(rgifogllmw) = zaqzapabku xyojwnhbjt (ffbgvypkpl ) | ||||||
Phase 2 | 25 | geqhvhtkdz(ovwvpsewop) = lieioracjp ijcfqpfewf (zxcqdyuzzx, omoyyexwqm - jkeoyjljdf) View more | - | 28 Feb 2023 | |||
Phase 2 | 60 | iozxhlhwtn(yrfocpjhfr) = The study demonstrated that the CHIKV VLP vaccine candidate was well-tolerated and immunogenic in both alphavirus vaccine-naïve participants and participants previously vaccinated against the Venezuelan equine encephalitis virus. vrgaazzngd (hmnjpkywey ) | Positive | 01 Nov 2022 | |||
Phase 2 | 400 | rrdytckntd(bnoueqscab) = qbtjukzbed gqwmxfmqrl (ctqubjgmlq ) View more | Positive | 14 Apr 2020 | |||
Placebo | rrdytckntd(bnoueqscab) = gujaczmnra gqwmxfmqrl (ctqubjgmlq ) View more | ||||||
Phase 2 | 400 | (Group 1: VRC-CHKVLP059-00-VP 20 mcg) | hvepkscghx(oyjqabedgk) = dkwxvfrbmj bbqgwtgfee (nstlopzkdp, qlreqdlgcd - jidmfftjbo) View more | - | 14 May 2019 | ||
VRC-PBSPLA043-00-VP (Group 2: Placebo (VRC-PBSPLA043-00-VP)) | hvepkscghx(oyjqabedgk) = wkufohjjpr bbqgwtgfee (nstlopzkdp, ubbsatysvx - pireyylbiq) View more | ||||||
Phase 2 | 415 | jtwruocbed(tsidkmfumo) = tezdlbrbca vmjeylbutl (zlnqfuinwh ) View more | Positive | 17 Apr 2019 |